Reviewer’s report

Title: Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: A cost effectiveness analysis for the Greek healthcare setting

Version: 4 Date: 17 January 2013

Reviewer: Shekoufeh Nikfar

Reviewer’s report:

1- Please provide: The reason that authors consider DPN and PHN but they didn’t mention other indications of gabapentin and pregabalin to control pain like fibromyalgia.

2- Please demonstrate the model figuratively. It will help it to be clear.

3- In sensitivity analysis: There is more important variable in cost that should be considered for consistency. The variation of cost because of prescribing divided doses of drugs should be considered.

4- I recommend the following article that has been published recently in same perspective to compared and discussed with this article: The effectiveness and cost-effectiveness of pregabalin in the treatment of diabetic peripheral neuropathy: A systematic review and economic model. International Journal of Pharmacology 2012; 8(6): 490-495.

5- Authors have claimed that “generic preparations of gabapentin were not included in the analysis due to their low penetration in the Greek healthcare market”. If at the same time generic preparations of pregabalin is available in market according to economic evaluation grid the result will show that use of gabapentin is dominated. Please explain this complexity.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

'I declare that I have no competing interests'